WHO Factsheet. 14 March 2016
Current Issüs Arising from Tuberculosis Screening with Interferon-Gamma- Release Assays (IGRAs)
Pneumologie 2015; 69: 271–275
A review of current literature and up date data from the field, April 2015.
This report has been published in part in J Hosp Inf. 2015;90:1-9.
http://www.ncbi.nlm.nih.gov/pubmed/?term=ebola+nosocomial+shears
Plos Neglected Tropical Diseases 8(11): e3229 (20 November 2014)
WHO GUIDELINES REVIEW COMMITTEE
The current guidelines on Integrated Management of Acute Malnutrition (IMAM), addresses the issue of improved management of severe acute malnutrition (SAM), particularly in children under 5 years of age. In the absence of standard protocols, mortality in children admitted to hospital with SAM can ra...nge between 20 -30% with the highest levels of 50-60% among those with oedematous malnutrition. With modern treatment regimens and improved access to treatment, case-fatality rates can be reduced to less than 5%. These provincial guidelines on IMAM in KZN, includes inpatient care protocols on the management of SAM, and outpatient and community outreach components to manage moderate acute malnutrition (MAM) and prevent deterioration to SAM.
more
« Programme Renforcement et Décentralisation de la Prévention et de
la prise en charge des PVVIH en RCA »
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more